Social Media Ideas for Tefrx

Trifast plc (TFSTF) Q4 2026 Earnings Call Transcript

Trifast plc (TFSTF) Q4 2026 Earnings Call Transcript

Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform

Templeton Emerging Markets Investment Trust plc (TXEMF) Shareholder/Analyst Call Transcript

Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Evere...

Terumo Corporation (TRUMY) Analyst/Investor Day Transcript

Telix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeutic and Diagnostic A...

T1 Energy (TE) Soars 23% as Hedge Fund Gobbles 10M Shares

TG Therapeutics rises on early-stage trial data for Briumvi injectable

EDAP TMS S.A. (FOCL) Analyst/Investor Day Transcript

PainTEQ Launches TRAQâ„¢, A Next-Generation Posterior Approach to SI Joint Fusion

PainTEQ announced the U.S. commercial launch of TRAQ™ SI Joint Fusion — the first posterior SI joint implant designed for bi-cortical fixation through a 1-inch incision.

TE Connectivity plc (TEL) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Evolutionary analysis of transcription elongation factors reveals conserved and lineage-specific regulatory domains

by Alex M. Francette, Aakash Grover, Nathan Clark, Karen M. Arndt In eukaryotes, transcription elongation factors (TEFs) associate with RNA Polymerase II (RNAPII) to facilitate ge...

PainTEQ Launches TRAQв„ў, A Next-Generation Posterior Approach to SI Joint Fusion

Spectral Medical Inc. (EDT:CA) Shareholder/Analyst Call Transcript

TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

TRNR Reports Q1 2026 Results, Driven By 279% Revenue Growth; Confirms 2026 Pro Forma Revenue Guidance of More Than $30m

Q1 2026 Reported Revenue of $5.1 Million, with Pro Forma Revenue of $7.7 Million and Pro Forma Adjusted EBITDA (non-GAAP) Loss of $1.1 MillionCompany Provides Q2 2026 Guidance Of A...

ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achiev...

- - • Data from the head-to-head study show efdoralprin alfa normalized and maintained functional AAT levels in people living with alpha-1 antitrypsin deficiency - • Efdoralpr...

Templeton Foreign Fund Q1 2026 Commentary

Ethyreal Bio manifests with $101M in pack of biotechs gunning for Amgen’s Tepezza

Ethyreal Bio has exited stealth with $101 million, joining the queue of companies preparing to challenge Amgen’s Tepezza.

Roth Capital Reiterates T1 Energy (TE) Rating After Recent Debate

Roth Capital Reiterates T1 Energy (TE) Rating After Recent Debate

TechPrecision Corporation (TPCS) Q4 2026 Earnings Call Transcript

FDA approves Tzield for children with new stage 3 type 1 diabetes

The U.S. Food and Drug Administration has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged 8...